Clinical Trials Directory

Trials / Unknown

UnknownNCT03016455

B Cell Lymphocyte in Humoral Rejection and Alloimmunisation

Status
Unknown
Phase
Study type
Observational
Enrollment
125 (estimated)
Sponsor
University Hospital, Brest · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study aims to better characterise B cell phenotype and functional abnormalities in kidney transplant patients producing donor specific antibody (DSA) and in those with chronic antibody mediated rejection (cAMR) and to search for a predictive tool (biomarker). The functional analysis will help to better understand B cell-dependant mechanisms implied in T cell proliferation and better target future treatments.

Detailed description

The principal objective is to better understand the B cell dependant mechanisms of the chronic antibody mediated rejection (cAMR). A particular focus will be done on the mechanisms that could explain the natural history of chronic humoral mediated rejection and of pathways from DSA negative status toward DSA positive status and from DSA positive status to histological lesions. The following will be undergone for three categories of patients (stable patients, DSA positive patients without cAMR and DSA positive patients with cAMR) : * A phenotypic analysis of B cells of patients suffering from chronic humoral rejection or who are simply DSA positive. * A functional analysis in autologous cultures in order to confirm our preliminary results. * A functional analysis in a heterologous proliferation test aiming at a better understanding of the absence of B cell regulation of T cell proliferation in patients suffering from cAMR. * A cytokine analysis (IL10, alpha-tumor necrosis factor, gamma-interferon dosing), for a better understanding of the mechanisms that are involved in the regulation of the T cell response that is induced by the B cells.

Conditions

Interventions

TypeNameDescription
OTHERPresence of DSA w/ cAMR
OTHERPresence of DSA w/o cAMR
OTHERNo DSA No cAMR

Timeline

Start date
2013-06-01
Primary completion
2017-12-01
Completion
2017-12-01
First posted
2017-01-10
Last updated
2017-05-04

Locations

13 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03016455. Inclusion in this directory is not an endorsement.